Concepts (119)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| beta-Lactamases | 8 | 2023 | 101 | 1.650 |
Why?
|
| Bacterial Proteins | 7 | 2023 | 91 | 1.560 |
Why?
|
| Pseudomonas aeruginosa | 3 | 2011 | 41 | 1.040 |
Why?
|
| Gram-Negative Bacteria | 3 | 2023 | 26 | 0.910 |
Why?
|
| Anti-Bacterial Agents | 6 | 2024 | 377 | 0.890 |
Why?
|
| Pseudomonas Infections | 3 | 2011 | 32 | 0.790 |
Why?
|
| Carrier State | 3 | 2024 | 62 | 0.710 |
Why?
|
| Molecular Diagnostic Techniques | 2 | 2018 | 9 | 0.700 |
Why?
|
| Gram-Negative Bacterial Infections | 2 | 2018 | 24 | 0.700 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2020 | 28 | 0.670 |
Why?
|
| Drug Resistance, Microbial | 1 | 2020 | 67 | 0.650 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 1 | 2019 | 7 | 0.650 |
Why?
|
| Anti-Infective Agents | 1 | 2020 | 31 | 0.640 |
Why?
|
| Immunocompromised Host | 1 | 2019 | 46 | 0.640 |
Why?
|
| Betacoronavirus | 1 | 2020 | 75 | 0.630 |
Why?
|
| Lung Diseases | 1 | 2019 | 46 | 0.630 |
Why?
|
| Klebsiella Infections | 5 | 2019 | 65 | 0.610 |
Why?
|
| Klebsiella pneumoniae | 5 | 2019 | 71 | 0.600 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 88 | 0.600 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 92 | 0.600 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2018 | 41 | 0.590 |
Why?
|
| Cross Infection | 6 | 2019 | 309 | 0.580 |
Why?
|
| Bacteriological Techniques | 1 | 2017 | 16 | 0.550 |
Why?
|
| beta-Lactam Resistance | 1 | 2017 | 14 | 0.550 |
Why?
|
| Microbial Sensitivity Tests | 3 | 2024 | 87 | 0.470 |
Why?
|
| Humans | 23 | 2024 | 27214 | 0.400 |
Why?
|
| Specimen Handling | 3 | 2023 | 44 | 0.350 |
Why?
|
| Enterobacteriaceae | 2 | 2024 | 45 | 0.340 |
Why?
|
| Carbapenems | 4 | 2023 | 46 | 0.320 |
Why?
|
| Drug Resistance, Bacterial | 4 | 2018 | 55 | 0.300 |
Why?
|
| Time Factors | 4 | 2020 | 1438 | 0.290 |
Why?
|
| Genomics | 2 | 2024 | 68 | 0.280 |
Why?
|
| Sensitivity and Specificity | 4 | 2022 | 486 | 0.260 |
Why?
|
| Gastrointestinal Microbiome | 2 | 2019 | 162 | 0.250 |
Why?
|
| Intensive Care Units | 2 | 2024 | 265 | 0.240 |
Why?
|
| Amoxicillin-Potassium Clavulanate Combination | 1 | 2024 | 2 | 0.230 |
Why?
|
| Rectum | 3 | 2024 | 52 | 0.230 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2024 | 73 | 0.220 |
Why?
|
| Clostridium Infections | 1 | 2023 | 24 | 0.210 |
Why?
|
| Infection Control | 2 | 2014 | 173 | 0.200 |
Why?
|
| Adult | 5 | 2024 | 7938 | 0.190 |
Why?
|
| Feces | 2 | 2024 | 103 | 0.190 |
Why?
|
| Female | 9 | 2024 | 15308 | 0.180 |
Why?
|
| Long-Term Care | 3 | 2017 | 61 | 0.180 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2020 | 6 | 0.170 |
Why?
|
| Nasopharynx | 1 | 2020 | 5 | 0.170 |
Why?
|
| Enterobacteriaceae Infections | 2 | 2024 | 57 | 0.170 |
Why?
|
| HIV-1 | 1 | 2022 | 235 | 0.170 |
Why?
|
| Middle Aged | 8 | 2024 | 9057 | 0.170 |
Why?
|
| Phage Therapy | 1 | 2020 | 2 | 0.170 |
Why?
|
| Mycobacterium xenopi | 1 | 2019 | 2 | 0.160 |
Why?
|
| Hospitals | 5 | 2019 | 170 | 0.150 |
Why?
|
| Bacteremia | 1 | 2019 | 100 | 0.150 |
Why?
|
| Pandemics | 1 | 2020 | 243 | 0.150 |
Why?
|
| United States | 2 | 2023 | 2076 | 0.150 |
Why?
|
| Kidney Transplantation | 1 | 2019 | 119 | 0.140 |
Why?
|
| Aged | 6 | 2024 | 9113 | 0.140 |
Why?
|
| HIV Infections | 1 | 2022 | 477 | 0.140 |
Why?
|
| Male | 8 | 2024 | 14852 | 0.130 |
Why?
|
| Bacteria | 1 | 2017 | 73 | 0.130 |
Why?
|
| Population Surveillance | 1 | 2017 | 115 | 0.130 |
Why?
|
| Predictive Value of Tests | 1 | 2017 | 478 | 0.120 |
Why?
|
| Chicago | 4 | 2024 | 953 | 0.120 |
Why?
|
| Medical Staff, Hospital | 1 | 2014 | 17 | 0.110 |
Why?
|
| Baths | 1 | 2014 | 31 | 0.110 |
Why?
|
| Chlorhexidine | 1 | 2014 | 64 | 0.110 |
Why?
|
| Skin | 1 | 2014 | 130 | 0.100 |
Why?
|
| Attitude of Health Personnel | 1 | 2014 | 146 | 0.100 |
Why?
|
| Prospective Studies | 1 | 2017 | 1784 | 0.090 |
Why?
|
| RNA, Ribosomal, 16S | 2 | 2024 | 57 | 0.090 |
Why?
|
| Virulence Factors | 1 | 2011 | 6 | 0.090 |
Why?
|
| Plasmids | 1 | 2011 | 44 | 0.090 |
Why?
|
| Cell Membrane Permeability | 1 | 2011 | 52 | 0.090 |
Why?
|
| Drug Therapy, Combination | 1 | 2011 | 168 | 0.090 |
Why?
|
| Disease Outbreaks | 2 | 2024 | 81 | 0.080 |
Why?
|
| Mutation | 1 | 2011 | 352 | 0.080 |
Why?
|
| Vancomycin-Resistant Enterococci | 1 | 2024 | 12 | 0.060 |
Why?
|
| Epidemiological Monitoring | 1 | 2024 | 15 | 0.060 |
Why?
|
| Monkeypox virus | 1 | 2024 | 2 | 0.060 |
Why?
|
| Biological Assay | 1 | 2024 | 7 | 0.060 |
Why?
|
| Cross Reactions | 1 | 2024 | 9 | 0.060 |
Why?
|
| Public Health | 1 | 2024 | 71 | 0.060 |
Why?
|
| Culture Media | 1 | 2024 | 31 | 0.060 |
Why?
|
| Delivery of Health Care | 1 | 2024 | 147 | 0.050 |
Why?
|
| Patient Discharge | 1 | 2024 | 151 | 0.050 |
Why?
|
| Virus Shedding | 1 | 2023 | 7 | 0.050 |
Why?
|
| Respiratory System | 1 | 2023 | 9 | 0.050 |
Why?
|
| RNA, Viral | 1 | 2023 | 48 | 0.050 |
Why?
|
| HIV Antigens | 1 | 2022 | 12 | 0.050 |
Why?
|
| HIV Antibodies | 1 | 2022 | 15 | 0.050 |
Why?
|
| HIV-2 | 1 | 2022 | 10 | 0.050 |
Why?
|
| Immunoassay | 1 | 2022 | 38 | 0.050 |
Why?
|
| ROC Curve | 1 | 2019 | 141 | 0.040 |
Why?
|
| Oregon | 1 | 2018 | 2 | 0.040 |
Why?
|
| Spain | 1 | 2018 | 8 | 0.040 |
Why?
|
| Italy | 1 | 2018 | 15 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2019 | 350 | 0.040 |
Why?
|
| Illinois | 1 | 2018 | 250 | 0.030 |
Why?
|
| DNA, Bacterial | 1 | 2017 | 41 | 0.030 |
Why?
|
| Temperature | 1 | 2017 | 62 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2017 | 57 | 0.030 |
Why?
|
| Gastrointestinal Tract | 1 | 2017 | 45 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2017 | 257 | 0.030 |
Why?
|
| Aged, 80 and over | 2 | 2015 | 4842 | 0.030 |
Why?
|
| Markov Chains | 1 | 2015 | 33 | 0.030 |
Why?
|
| Comorbidity | 1 | 2017 | 488 | 0.030 |
Why?
|
| Monte Carlo Method | 1 | 2015 | 50 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2017 | 589 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2019 | 1380 | 0.030 |
Why?
|
| Models, Statistical | 1 | 2015 | 127 | 0.030 |
Why?
|
| Organizational Culture | 1 | 2014 | 17 | 0.030 |
Why?
|
| Hospital Administration | 1 | 2014 | 25 | 0.030 |
Why?
|
| Health Care Surveys | 1 | 2014 | 64 | 0.030 |
Why?
|
| Focus Groups | 1 | 2014 | 88 | 0.030 |
Why?
|
| Prevalence | 1 | 2015 | 458 | 0.030 |
Why?
|
| Qualitative Research | 1 | 2014 | 114 | 0.030 |
Why?
|
| Biomarkers | 1 | 2015 | 561 | 0.020 |
Why?
|
| Hospitalization | 1 | 2014 | 315 | 0.020 |
Why?
|
| Risk Factors | 1 | 2017 | 2336 | 0.020 |
Why?
|